CAR-T cells for active residual disease in large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a type of personalized cell therapy called CAR-T cells for people with large B-cell lymphoma who still have cancer left after initial treatment. The goal is to see if these cells can eliminate the remaining cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of large B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL) or transformed follicular lymphoma.
- You have completed your first round of chemotherapy and immunotherapy, but tests still show signs of cancer in your body.
- You are 18 years or older.
- You are in generally good health (able to care for yourself and up and about).
- You have not received CAR-T cell therapy or a stem cell transplant from a donor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment for people with B-cell lymphoma that has come back or not responded to standard treatments. CAR-T cells are specially engineered immune cells that target and kill lymphoma cells. The study aims to see if this treatment is safe and effective.
This study tests a new CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments, including an FDA-approved CAR T-cell therapy. The goal is to see if this new therapy can help when previous CAR T treatment has not worked.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
Hear when a new Large-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.